Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis

Shujie Chen(Sir Run Run Shaw Hospital), Lu Zhang(Sir Run Run Shaw Hospital), Mengjie Li(Sir Run Run Shaw Hospital), Ying Zhang(Sir Run Run Shaw Hospital), Meng Sun(Sir Run Run Shaw Hospital), Lingfang Wang(Women's Hospital, School of Medicine, Zhejiang University), Jiebo Lin(Women's Hospital, School of Medicine, Zhejiang University), Yun Cui(Sir Run Run Shaw Hospital), Qian Chen(Sir Run Run Shaw Hospital), Chenqi Jin(Sir Run Run Shaw Hospital), Xiang Li(Sir Run Run Shaw Hospital), Boya Wang(Sir Run Run Shaw Hospital), Hao Chen(Southern University of Science and Technology), Tianhua Zhou(Sir Run Run Shaw Hospital), Liangjing Wang(Women's Hospital, School of Medicine, Zhejiang University), Chih-Hung Hsu(Women's Hospital, School of Medicine, Zhejiang University), Wei Zhuo(Sir Run Run Shaw Hospital)
Nature Communications
March 10, 2022
Cited by 235Open Access
Full Text

Abstract

Abstract Microbiota-host interactions play critical roles in colorectal cancer (CRC) progression, however, the underlying mechanisms remain elusive. Here, we uncover that Fusobacterium nucleatum ( F. nucleatum ) induces a dramatic decline of m 6 A modifications in CRC cells and patient-derived xenograft (PDX) tissues by downregulation of an m 6 A methyltransferase METTL3, contributing to inducation of CRC aggressiveness. Mechanistically, we characterized forkhead box D3 (FOXD3) as a transcription factor for METTL3. F. nucleatum activates YAP signaling, inhibits FOXD3 expression, and subsequently reduces METTL3 transcription. Downregulation of METTL3 promotes its target kinesin family member 26B (KIF26B) expression by reducing its m 6 A levels and diminishing YTHDF2-dependent mRNA degradation, which contributes to F. nucleatum -induced CRC metastasis. Moreover, METTL3 expression is negatively correlated with F. nucleatum and KIF26B levels in CRC tissues. A high expression of KIF26B is also significantly correlated with a shorter survival time of CRC patients. Together, our findings provide insights into modulating human m 6 A epitranscriptome by gut microbiota, and its significance in CRC progression.


Related Papers